References
- 2020 Alzheimer’s Disease Facts and Figures [Internet]. Chicago (IL): Alzheimer’s Association; c2020 [cited 2020 Dec 18]. Available from: https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf
- Pasqualetti G, Tognini S, Calsolaro V, et al. Potential drug–drug interactions in Alzheimer patients with behavioral symptoms. Clin Interv Aging. 2015;10:1457–1466.
- 2017 National Population Projections Tables: Main Series [Internet]. The United States Census Bureau [cited 2020 Dec 18]. Available from: https://www.census.gov/data/tables/2017/demo/popproj/2017-summary-tables.html
- Hebert LE, Weuve J, Scherr PA, et al. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–1783.
- Smith D, Lovell J, Weller C, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One. 2017;12(2):e0170651.
- Centers for Medicare & Medicaid Services. HHS. Medicare program; Medicare prescription drug benefit. Final rule. Fed Regist. 2005;70:4193–4585.
- Medicare Program; Contract Year 2015 Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs; Proposed Rule [Internet]. Department of Health and Human Services; 2014 [cited 2020 Dec 18]. Available from: https://www.govinfo.gov/content/pkg/FR-2014-01-10/pdf/2013-31497.pdf
- American Pharmacists Association, National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc. 2008;48(3):341–353.
- Medication Therapy Management [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services; 2020 [cited 2020 Dec 18]. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/MTM
- Stuart B, Hendrick FB, Shen X, et al. Eligibility for and enrollment in Medicare Part D Medication Therapy Management Programs varies by plan sponsor. Health Aff. 2016;35(9):1572–1580.
- Gray C, Cooke CE, Brandt N. Evolution of the Medicare Part D Medication Therapy Management Program from inception in 2006 to the present. Am Health Drug Benefits. 2019;12(5):243–249.
- Perlroth D, Marrufo G, Montesinos A, et al. Medication therapy management in chronically ill populations: final report [Internet]. Burlingame (CA): Acumen LLC; 2013 [cited 2020 Dec 18]. Available from: https://innovation.cms.gov/files/reports/mtm_final_report.pdf
- Ai AL, Carretta H, Beitsch LM, et al. Medication therapy management programs: promises and pitfalls. J Manag Care Spec Pharm. 2014;20(12):1162–1182.
- Viswanathan M, Kahwati LC, Golin CE, et al. Medication therapy management interventions in outpatient settings: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(1):76–87.
- CY 2017 Medication Therapy Management Program Guidance and Submission Instructions [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services; 2016 [cited 2020 Dec 18]. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Memo-Contract-Year-2017-Medication-Therapy-Management-MTM-Program-Submission-v-040816.pdf
- Part C and D Performance Data [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services; 2020 [cited 2020 Dec 18]. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/PerformanceData
- Data File Search [Internet]. Minneapolis (MN): Research Data Assistance Center [cited 2020 Dec 18]. Available from: https://www.resdac.org/cms-data?tid_1%5B%5D=1
- Area Health Resources Files [Internet]. Health Resources & Services Administration; 2020 [cited 2020 Dec 18]. Available from: https://data.hrsa.gov/topics/health-workforce/ahrf
- Condition Categories [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services Chronic Conditions Data Warehouse; 2020. Alzheimer’s Disease and Related Disorders or Senile Dementia [cited 18 Dec 2020]. Available from: https://www2.ccwdata.org/web/guest/condition-categories
- CY 2016 Medication Therapy Management Program Guidance and Submission Instructions [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services; 2015 [cited 18 Dec 2020]. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/Memo-Contract-Year-2016-Medication-Therapy-Management-MTM-Program-Submission-v-040715.pdf
- 2016 Medicare Part D Medication Therapy Management (MTM) Programs [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services; 2016 [cited 18 Dec 2020]. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/CY2016-MTM-Fact-Sheet.pdf
- 2017 Medicare Part D Medication Therapy Management (MTM) Programs [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services; 2017 [cited 18 Dec 2020]. Available from: https://www.cms.gov/Medicare/Prescription-Drug-Coverage/PrescriptionDrugCovContra/Downloads/CY2017-MTM-Fact-sheet.pdf
- Daniel GW, Malone DC. Characteristics of older adults who meet the annual prescription drug expenditure threshold for Medicare Medication Therapy Management Programs. J Manag Care Spec Pharm. 2007;13(2):142–154.
- Part D Event File [Internet]. Minneapolis (MN): Research Data Assistance Center [cited 2020 Dec 18]. Available from: https://www.resdac.org/cms-data/files/pde
- Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70(1):41–55.
- Austin PC. A comparison of 12 algorithms for matching on the propensity score. Stat Med. 2014;33(6):1057–1069.
- Strom BL. Pharmacoepidemiology, 4th ed. Hoboken (NJ): John Wiley & Sons; 2005.
- Measures Overview [Internet]. Alexandria (VA): Pharmacy Quality Alliance; c2018 [cited 2020 Dec 18]. Available from: https://www.pqaalliance.org/measures-overview.
- Gelberg L, Andersen RM, Leake BD. The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Serv Res. 2000;34(6):1273–1302.
- Kaushik V, Smith ST, Mikobi E, et al. Acetylcholinesterase inhibitors: beneficial effects on comorbidities in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2018;33(2):73–85.
- Campbell NL, Perkins AJ, Gao S, et al. Adherence and tolerability of Alzheimer’s disease medications: a pragmatic randomized trial. J Am Geriatr Soc. 2017;65(7):1497–1504.
- Tan EC, Hilmer SN, Garcia-Ptacek S, et al. Current approaches to the pharmacological treatment of Alzheimer’s disease. Aust J Gen Pract. 2018;47(9):586–592.
- Giberson S, Yoder S, Lee MP. Improving Patient and Health System Outcomes through Advanced Pharmacy Practice. A Report to the U. S. Surgeon General. Office of the Chief Pharmacist. U.S. Public Health Service; 2011 [cited 2020 Dec 18]. Available from: https://www.accp.com/docs/positions/misc/improving_patient_and_health_system_outcomes.pdf
- Fan B, Ghimire E, Habibulla A, et al. Evaluation of the Part D Enhanced Medication Therapy Management (MTM) Model: First Evaluation Report. Burlingame (CA). Acumen LLC; 2019 [cited 2020 Dec 18]. Available from: https://downloads.cms.gov/files/mtm-firstevalrpt.pdf
- Pestka DL, Zillich AJ, Coe AB, et al. Nationwide estimates of Medication Therapy Management delivery under the Medicare prescription drug benefit. J Am Pharm Assoc. 2020;60(3):456–461.
- Medicare 2021 Part C & D Star Ratings Technical Notes [Internet]. Baltimore (MD): Centers for Medicare & Medicaid Services; 2020 [cited 18 Dec 2020]. Available from: https://www.cms.gov/files/document/2021technotes20201001.pdf-0
- Brandt NJ, Cooke CE, Sharma K, et al. Findings from a national survey of Medicare beneficiary perspectives on the Medicare Part D Medication Therapy Management Standardized Format. J Manag Care Spec Pharm. 2019;25(3):366–391.
- Sharma K, Cooke CE, Howard AK, et al. Beneficiary, caregiver, and case manager perspectives on the Medication Therapy Management Program Standardized Format. J Gerontol Nurs. 2019;45(4):7–13.